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Abstract 
The elastin degradation products, desmosine (DES) and isodesmosine (IDES) are highly 
stable, cross-linking amino-acids that are unique to mature elastin. The excretion of 
DES/IDES in urine, in the free form and with associated peptide fragments, provides an 
indicator of lung damage in chronic obstructive pulmonary disease (COPD). A quantitative 
ion mobility-mass spectrometry (IM-MS) method has been developed for the analysis of free 
DES/IDES in urine with deuterated IDES as an internal standard. 
Resolution of DES/IDES isomers was achieved in less than five minutes using ultra 
performance liquid chromatography (UPLC) combined with ion pairing. The optimized 
UPLC-IM-MS method provided a linear dynamic range of 10-300 ng/mL and a limit of 
quantitation of 0.028 ng/mL for IDES and 0.03 ng/mL for DES (0.55 ng and 0.61 ng on 
column respectively). The method reproducibility (%RSD) was < 4% for DES and IDES. 
The UPLC-IM-MS method was applied to the analysis of urine samples obtained from 
healthy volunteers and COPD patients. The DES/IDES concentrations in healthy and 
COPD urine showed an increase in DES (79%) and IDES (74%) in the COPD samples, 
relative to healthy controls. The incorporation of an IM separation prior to m/z measurement 
by MS was shown to reduce non-target ion responses from the bio-fluid matrix. 
 
Keywords: Ion Mobility-Mass Spectrometry, Urinary Analysis, COPD, Desmosine, 
Isodesmosine. 
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1. Introduction 
Chronic obstructive pulmonary disease (COPD) is defined as a completely irreversible, 
progressive air flow obstruction, associated with lung inflammation caused by prolonged 
exposure to noxious particles and gases, particularly tobacco smoke [1]. The term COPD 
includes a variety of pathological disorders characterized by acute inflammatory processes 
that present identical symptoms; these include bronchitis, asthma, cystic fibrosis, acute lung 
injury, emphysema and alpha-1-antiprotease deficient patients [2]. 
These inflammatory reactions to exogenous [3] and genetic factors [4-6], initiate the 
recruitment (chemotaxis) of the cells involved in the immune system [7]. COPD is still 
under-diagnosed with approximately half of severe/very severe patients in the United 
Kingdom having any form of respiratory diagnosis [8]. 
The prognosis of COPD at the severe/very severe stages is poor with, currently, no prospect 
to reverse lung degradation [9]. The early detection and stratification of COPD patients can 
enable more focused treatment regimes to be employed [9-11] and a variety of biomarker 
candidates have been tested through multi-center clinical based trials [11]. 
Biomarkers identified include the elastin degradation product desmosine (DES) and its 
isomer isodesmosine (IDES). DES and IDES are pyridinium ring containing amino acids 
(Figure 1) produced by the aggregation of four lysine residues [12], which form the highly 
stable cross-links unique to elastin. During the lung repair process, DES and IDES molecules 
are liberated from the extracellular matrix (ECM) in the free form (15%) and bound form, 
associated with peptide fragments (85%). Concentrations range from 0.5 – 3 μg/g creatinine 
and 5 – 14 μg/g creatinine for free and total DES/IDES, respectively, in healthy subjects [13, 
14], normalized to urinary creatinine to adjust for individual variation in sample volume and 
rate of urine production [15]. The presence of DES/IDES in the human body is independent 
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of diet and is elimination route specific to urine [16]. These factors make DES and IDES 
potentially important biomarkers for detection and monitoring of COPD [17-20]. 
The analytical determination of DES/IDES has been previously reviewed by Viglio et al. 
[21], with reported methods including amino-acid analysis, radio-immunoassay (RIA) and 
enzyme-linked immunosorbant assays (ELISA). These methods were of limited clinical 
practicality due to extensive sample preparation required and false positives resulting from 
cross-reactivity [19]. The majority of recent studies for the detection and quantitation of 
DES/IDES, have employed high performance liquid chromatography-mass spectrometry 
(LC-MS) [13,14, 22-25] with ion-pairing for the separation of DES/IDES on ODS based 
stationary phases, due to the cationic nature of these analytes.  
Ma et al. [13, 14] applied LC-MS and LC-MS/MS to the separation of DES/IDES in healthy 
urine, with a partial separation of DES/IDES peaks achieved in 35 minute LC run. The LDR 
of their method (0.1 – 50 ng on column; based on standards), indicated the potential of 
applying an ion pairing liquid chromatography approach to the quantification of free 
DES/IDES in urine. Recently, Albarbarawi et al. [24] reported the LC-MS/MS analysis of 
total (free and bound) DES/IDES to predict the extent of lung damage based upon the 
combined DES/IDES response, but without chromatographic separation of the isomers. An 
ultra performance liquid chromatography (UPLC) approach has been reported by Shiraishi et 
al. [25], with a chromatographic run time of 15 minutes for the determination of total 
DES/IDES after bound DES/IDES was released by acid hydrolysis. These studies reported 
DES/IDES levels to increase (approximately 100%) in COPD affected individuals, relative to 
healthy patients. However, the liberation of free DES/IDES from associated peptide 
fragments requires a lengthy acid hydrolysis procedure, typically taking over 24-48 hours. 
This paper reports an evaluation of the potential of ion mobility-mass spectrometry (IM-MS) 
combined with UPLC, for the quantitative determination of free DES/IDES in urine. The 
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incorporation of ion mobility (IM) spectrometry, [26-28] allows gas-phase separation of ions 
based on their rotationally-averaged collisional cross-section (i.e. size and shape) prior to m/z 
measurement using time-of-flight mass spectrometry. IM-MS has been shown to enhance the 
separation of complex samples such as urine [29] and the resolution of isomeric compounds, 
[30] but the future potential of the technique for the quantitative bioanalysis of small 
molecules has received little attention. The IM-MS method developed gives baseline 
chromatographic separation of free DES and IDES without a lengthy hydrolysis sample 
preparation step and demonstrates good quantitative performance. The determination of free 
DES/IDES at physiological levels, as biomarkers for discrimination between healthy and 
COPD-affected individuals, is demonstrated for disease vs control pooled urine samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6 
2. Experimental 
 
2.1. Chemicals 
Elastin soluble DES, IDES and deuterated D9-IDES were provided by AstraZeneca R&D 
(Charnwood, Loughborough, UK). Acetonitrile (analytical grade), methanol (analytical 
grade), water (analytical grade), ammonium formate (>99.9%) and sodium acetate (analytical 
grade) were purchased from Fisher Scientific (Loughborough, UK). Heptafluorobutyric acid, 
HFBA, (>99%) was purchased from Acros Organics (Geel, Belgium). HPLC grade formic 
acid (>99.9%) and creatinine (>99%) was purchased from Sigma-Aldrich (Gillingham, UK). 
 
2.2. Preparation of DES, IDES and D9-IDES Standards 
Standards of DES and IDES with concentrations 10, 25, 50, 100, 200, 300, 400 and 500 
ng/mL were prepared, each containing 25 ng/mL of D9-IDES. All solutions were freshly 
prepared in 85:15 H2O : H2O:MeOH (60:40) (v/v) containing 5 mmol/L ammonium formate, 
0.1% (v/v) HFBA and pH buffered to 2.5 using formic acid. 
 
2.3. UPLC Chromatographic Conditions 
The chromatographic separations were performed using a Waters AQUITY UPLC (Waters, 
Manchester, UK). DES/IDES separation was achieved on an AQUITY BEH C18 column (2.1 
x 100 mm, 1.7 μm Waters, Manchester, UK) under isocratic conditions with a flow rate of 
600 μL/min and an injection volume of 20μL. Mobile phase A consisted of 5 mmol/L 
ammonium formate in H2O with 0.1% (v/v) HFBA. Mobile phase B consisted of 5 mmol/L 
ammonium formate in 60:40 H2O: MeOH with 0.1% (v/v) HFBA, each buffered to a pH of 
2.5 using formic acid. A 5 minute isocratic flow of 85:15 mobile phase A: mobile phase B 
was used to elute DES and IDES. The mobile phase composition was then raised to 100% of 
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mobile phase B for 0.5 min before returning to the starting conditions. The total run time was 
6 minutes. 
 
2.4. IM-MS Conditions 
IM-MS analyses were carried out on a Waters Synapt HDMS spectrometer (Waters, 
Manchester, UK) using an ESI source operated in positive ionisation mode with enhanced 
duty cycle (EDC) set at m/z 526 to transport the DES/IDES and D9-IDES ions. The source 
and desolvation temperatures were set to 150°C and 450°C, gas flow (N2) rates were set to 50 
L/h and 1000 L/h respectively. The tri-wave drift cell conditions were set at 20 mL/min drift 
gas (N2) with a travelling wave height/velocity of 5 V and 300 m/s. IM-MS allowed nested 
mass spectra (0.065 ms/scan) and ion mobility spectra (13 ms/scan) to be acquired within the 
timescale of a typical UPLC peak, width a 2 s full with at half maximum (FWHM). The 
acquired UPLC-IM-MS data was processed using DriftScope and MassLynx 4.1 (Waters, 
Manchester, UK). 
 
2.5. Urine Sample Preparation 
Urine samples obtained from healthy volunteers and COPD patients were provided by 
AstraZeneca R&D Charnwood. To 1 mL of a combined (male and female) urine sample, 80 
μL of a 3.8 nmol/mL D9-IDES solution and 120 μL of 10% HFBA solution were added. The 
solution was then subjected to SPE clean-up on an Oasis HLB 30 mg cartridge (Waters, 
Manchester, UK). The cartridge was conditioned with 1 mL of acetonitrile (ACN) containing 
1% (v/v) HFBA and then equilibrated using 1 mL of aqueous 1% (v/v) HFBA. Urine samples 
(1.2 mL) were loaded onto the Oasis HLB solid phase, the column was washed with 1 mL of 
aqueous 1% (v/v) HFBA and eluted with 1 mL of 1% (v/v) HFBA in ACN. The extracts were 
then frozen (-80 °C) until required. 
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Prior to analysis, the urine extracts were thawed, evaporated to dryness using a TurboVap 
LV system (Biotarge AB, Uppsala Sweden) and reconstituted in 30 μL of freshly prepared 
H2O:MeOH (94:6, v/v) containing 0.1% (v/v) HFBA ion pairing reagent, buffered to pH 2.5 
using formic acid and ammonium formate. 
 
2.6. Creatinine Determination 
The creatinine concentration in pooled urine samples was determined using an Agilent 1200 
HPLC system with isocratic mobile phase (80:20 (v/v) H2O:MeOH and 10 mmol/L sodium 
acetate) flowing at 1.8 mL/min through a SCX HYPERSIL column (4.6 x 100 mm, 5 μm, 
Capital HPLC Ltd).UV detection was carried out (230 nm) with a total run time of 2 minutes. 
Urine samples were diluted (1:4, v/v) with 80:20 (v/v) (H2O:MeOH) mobile phase prior to 
injection (5 μL). Urinary creatinine concentrations were calculated based on a calibration 
curve (R
2
 = 0.99) of known creatinine standards, prepared at concentrations of 0.1, 0.5, 1, 2, 3 
and 5 mmol/L. 
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3. Results and Discussion 
 
3.1. UPLC-IM-MS analysisof DES/IDES standards. 
 
The rapid UPLC chromatographic analysis of DES/IDES was achieved using isocratic elution 
with methanol/water containing HFBA ion pairing reagent, buffered using formic 
acid/ammonium formate (Figure 2a) The separation of DES/IDES was achieved with a total 
chromatographic run time of 6 minutes, compared to a 15 minute run time previously 
reported [25] which is more suitable for high-throughput screening than reported previously 
[24, 25]. Optimization of the mobile phase combined with the UPLC (5 µm) stationary phase 
enabled baseline resolution (Rs = 1.9) of the DES/IDES isomers with good inter-day 
retention time reproducibility (%RSD) of 2.6% and 3.1% respectively. The DES/IDES ion 
drift time vs. retention time profile is shown in Figure 2b. The mobility range for DES (TOF 
scans/bins 96-126, td 6.24-8.19 ms) was higher than that of IDES (TOF scans/bins 89-121, td 
5.78-7.86 ms), indicating small differences in the rotationally averaged cross-sections, but the 
DES/IDES isomers were not resolved by ion mobility drift time. The drift time (bin) window 
selected for the maximum response of both DES and IDES isomers was in the range 7.22-
7.35 ms, indicated by the dotted line in Figure 2b, which provided the best compromise 
between analytical sensitivity and mobility selectivity, and was used in subsequent analyses. 
Optimized UPLC conditions were tested using a series of DES/IDES standards (10-500 
ng/mL), each spiked with deuterated D9-IDES (25 ng/mL) to determine linear dynamic 
ranges (LDR), limit of quantitation (LOQ) and the reproducibility in IM-MS mode. The LDR 
of the UPLC-IM-MS method was determined to be 10-300 ng/mL (r
2
 = 0.99) for DES and 
IDES, respectively (Figure 3).  
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The use of IM-MS in quantitative bioanalysis presents a challenge because of the reduced 
dynamic range of the IM technique and the LDR in IM-MS mode is significantly lower than 
in MS mode, because of detector saturation at higher concentrations resulting from the pulsed 
injection of ions into the drift cell. Nevertheless, the LDR is compatible with the expected 
range of concentrations for free DES/IDES in urine from COPD patients and healthy 
controls, making IM-MS suitable for clinical studies. The limit of quantitation (10:1 
signal/noise ratio) was 0.028 ng/mL and 0.03 ng/mL (0.55 ng and 0.61 ng on column) for 
IDES and DES respectively. The LOQ values are equivalent to 0.98 μg/g creatinine and 1.07 
μg/g creatinine for IDES and DES respectively assuming a standard creatinine concentration 
of 5 mmol/L. Sensitivity levels achievable using UPLC-IM-MS allows quantitation of free 
DES/IDES in urine, removing the requirement for the lengthy hydrolysis process (24-48h), 
used previously for the determination of total DES/IDES [13, 14, 23, 24]. Method 
reproducibility was determined for a DES/IDES concentration in the middle of the LDR (100 
ng/mL) over three consecutive days giving inter-day % RSDs (n=9) of 3.4% and 3.9% for 
DES and IDES, respectively, comparable with previously reported data [24]. The comparable 
precision and improved run time of the UPLC-IM-MS method demonstrates that there is no 
reduction in analytical quality associated with separation of the DES and IDES and doing so 
allows an assessment of DES/IDES variation across subjects. These data demonstrate that the 
linearity, sensitivity and reproducibility of the UPLC-IM-MS method are satisfactory for the 
quantitation of free DES/IDES in a clinical based setting, in accordance with the FDA 
guidance for industry bioanalytical method validation [31] and at physiologically relevant 
levels [13]. 
 
3.2. UPLC-IM-MS analysis of healthy and COPD urine. 
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The UPLC-IM-MS determination of free DES/IDES was assessed using pooled samples of 
healthy male urine, healthy female urine and COPD patient urine. Pooled healthy urine 
samples (three male and three female subjects) were selected based upon their creatinine 
content (3-15 mmol/L and 3-8 mmol/L for males and females respectively). These were 
chosen to represent the variation of urinary creatinine between individuals [32]. The pooled 
COPD urine samples (5.8 mmol/L) consisted of six individuals (both male and female) with a 
range of COPD diagnoses ranging from moderate to severe. The extracted ion 
chromatograms (m/z 526) for the analysis of a pooled COPD urine sample are shown in 
Figure 4. The retention times for free DES/IDES in the urine extract were slightly shorter 
than observed for DES/IDES standards under identical conditions. The assignment of the 
peaks at retention times of 3.0 and 3.3 minutes for DES and IDES respectively was 
confirmed by a standard addition of DES/IDES to a healthy urine sample. The DES/IDES 
peaks in the spiked healthy urine sample eluted from the column earlier (by approximately 30 
seconds) than DES/IDES standards that were run before and after the spiked urine (data not 
shown). The result indicates that the urine matrix has a significant effect on free DES/IDES 
retention. However, the DES and IDES retention times were consistent for all the urine 
samples analyzed, with co-elution of IDES/ D9- IDES, and the analyte resolution was still 
achieved, making quantitative measurements possible using the IDES-D9 internal standard.  
The selected ion chromatogram shown in Figure 4a represents an acquisition where the ion 
mobility data (TOF scans/bins 1-200) have been combined, generating a response equivalent 
to UPLC-MS without ion mobility separation. Figure 4c illustrates the selected ion response 
in UPLC-IM- MS mode, where a five bin window (TOF scans/bins 115-120, td 7.36-7.68 ms) 
was selected, showing a comparable signal to noise ratio. The effectiveness of the ion-
mobility separation is illustrated in Figure 4 (b) and (d) which shows the mass spectra 
corresponding to UPLC-MS (Figure 4(b)) and UPLC-IM-MS (Figure 4(d)) analyses at the 
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retention time for DES. The intensity of the DES ion (m/z 526) in the IM-MS spectrum is 
enhanced relative to matrix ions, demonstrating that ion mobility based separation combined 
with MS can improve mass spectral quality. 
An on column LOQ of 0.61 ng and 0.55 ng of DES/IDES equivalent to 0.98 μg/g 
creatinine and 1.07 μg/g creatinine (assuming 5 mmol/L creatinine) in urine was achieved for 
all three urine samples following the SPE pre-concentration and clean-up described in 
Section 2.5, and UPLC-IM-MS analysis. Data were normalized to creatinine concentrations 
in pooled urine samples (to adjust for individual glomular filtration rates), which were 
determined by UV ion-exchange chromotography (Section 2.6). Concentrations of free 
DES/IDES (μg/g creatinine) are shown in Figure 5. The quantitative UPLC-IM-MS analysis 
shows comparatively higher levels of free DES/IDES in COPD urine than control (male and 
female) urine with increases in concentration of 79% and 74% respectively. These results 
indicate the potential clinical applicability of the UPLC-IM-MS method for the distinction of 
healthy and COPD-affected individuals using DES and IDES as urinary biomarkers, 
potentially enabling targeted treatment strategies based on individual patient need. 
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4. Conclusions 
The development of a UPLC-IM-MS method is reported for the rapid separation (Rs > 1.5) 
and determination (6 minute analysis time) of the elastin cross-linking molecules DES and 
IDES, using ion-pair chromatography under isocratic conditions, with good precision (< 4% 
RSD, n =9). The method has been applied to determination of free DES/IDES in pooled urine 
samples obtained from healthy and COPD-affected individuals, using isotope dilution with 
D9-IDES and minimal sample preparation. Ion mobility-based separation enhanced the mass 
spectral ion intensities of DES/IDES and D9-IDES, relative to matrix ions, compared to 
UPLC-MS without ion mobility separation, reducing non-target interferences and allowing 
urine samples from healthy and COPD-affected individuals to be distinguished based solely 
upon free DES and IDES levels. The method shows increased throughput and selectivity, 
applicable to the rapid, non-invasive biomarker screening in a clinical setting, and 
demonstrates the future potential of IM-MS for quantitative bioanalysis.  
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Figure. 1. Chemical structures of the elastin cross-linking isomers (a) desmosine and (b) 
isodesmosine, [M]
+
 = 526.2877. 
 
 
 
 
 
Figure. 2. UPLC-IM-MS separation of DES/IDES standards (Rs = 1.9) (a) selected ion 
chromatograms for DES, IDES, m/z 526.29 ± 0.05 (300 ng/mL), and D9-IDES, m/z 535.34 ± 
0.05, (25 ng/mL). (b) Mobility vs m/z profile for DES and IDES (TOF scans/bins 1-200). 
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Figure. 3. Quantitative UPLC-IM-MS response for (a) DES and (b) IDES normalized to D9-
IDES internal standard. 
 
 
 
 
 
Figure. 4. Analysis of pooled COPD urine (a) selected ion response for m/z 526.29 ± 0.05 in 
UPLC-MS mode, (b) associated MS spectrum at FWHM of DES peak, (c) selected ion 
response for m/z 526.29 ± 0.05 in UPLC-IM-MS mode (TOF scans/bins 115-120), (d) 
associated IM-MS spectrum at FWHM of DES peak. 
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Figure. 5. Free DES/IDES concentrations (µg/g creatinine) in pooled healthy female, pooled 
healthy male and pooled COPD urine, error bars indicate standard error of the mean. 
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